Salkind Gene 4

What Happened

• Gene Salkind, a director of Coeptis Therapeutics Holdings, acquired shares on Feb 11, 2026 by exercising stock options and by receiving a restricted-stock grant. He exercised options that resulted in 5,700 common shares at an exercise price of $10.56 per share (total cost $60,192) and was granted 3,250 restricted shares valued at $0 in the filing.

Key Details

• Transaction dates: Feb 11, 2026 (reported on Form 4 filed Feb 13, 2026).
• Exercise (code M): 5,700 shares acquired at $10.56 each; total exercise cost indicated $60,192. (Footnote F1: $10.56 is the option exercise price.)
• Grant (code A): 3,250 restricted shares issued at $0.00 (Footnote F2: grant issued in connection with an option-exchange program where underwater options were surrendered).
• Ownership note: Filing indicates holdings include 4,211 shares held JTWROS with Catherine Salkind (Footnote F3). The filing does not state a complete post-transaction total beyond that note.
• Timeliness: Transaction reported on Feb 13 for Feb 11 activity — appears to have been filed within the normal Form 4 reporting window.

Context

• Exercising options (code M) means the insider converted vested options into common shares by paying the exercise price; no sale of the resulting shares was reported, so this was an acquisition of stock rather than a cashless sale.
• The 3,250 restricted shares were granted as part of an option-exchange program (surrendering underwater options), which is a compensation/accounting-driven action and not the same as an open-market purchase.
• These are acquisitions (insider obtaining shares), which can be of interest to investors, but filings do not explain the insider’s motivation.